0001477932-26-001517
SEC filingCreative Medical Technology Holdings, Inc. (CELZ) reported minimal revenue of $6K for FY2025 ending December 31, 2025, down 45% from $11K in FY2024, primarily due to decreased CaverStem sales amid strategic reevaluation. Gross profit was $4K, reflecting cost of revenues at $2K. Operating expenses rose to $6.1M, driven by $2.3M in R&D and $3.8M in SG&A, resulting in an operating loss of -$6.1M, wider than prior year. Net loss attributable to CMTH was -$6.0M or -$3 per share (basic/diluted, 2.4M weighted shares), compared to -$5.5M or -$3.71 prior year. Balance sheet strengthened with cash at $7.2M (up from implied prior), total assets $7.8M, and stockholders' equity $7.5M. Operating cash use was -$5.9M, offset by $7.2M financing inflows from warrant exercises, yielding $1.3M net cash increase. Management notes sufficient cash through at least March 2027 but anticipates future capital raises for clinical trials in Type 1 Diabetes (CELZ-201 CREATE-1) and back pain (CELZ-201 ADAPT), highlighting biotech development risks and low revenue base.
Creative Medical Technology Holdings, Inc. posted FY2025 revenue of $6K, a 45% decline from $11K in FY2024, due to reduced CaverStem kit sales as marketing efforts are paused for reevaluation. Gross profit fell to $4K from $6.6K. Operating expenses increased 7% to $6.1M, with R&D at $2.3M (down 6% YoY) and SG&A up 16% to $3.8M from higher salaries, marketing, and insurance. Operating loss widened to -$6.1M from -$5.7M. Interest income of $148K reduced net loss to -$6.0M or -$3 per share (2.4M weighted shares), versus -$5.5M or -$3.71 prior year. Cash position improved to $7.2M, supported by financing.
Revenue solely from CaverStem kits at $6K, down from $11K YoY, as management reevaluates strategy and explores partnerships. No segment breakdown disclosed; single reportable operating segment in immunotherapy, endocrinology, urology, neurology, orthopedics. Minimal commercialization; focus on clinical-stage assets like CELZ-201 for diabetes and back pain. No geographic mix specified; U.S.-centric operations.
Gross margin improved slightly to 66.7% from 60%, on lower COGS $2K versus $4.4K. Operating margin deeply negative at -101,667% due to high fixed costs in R&D/SG&A overwhelming negligible revenue. No EBITDA disclosed. Losses driven by clinical trial investments (e.g., ADAPT trial enrollment complete) and iPSC development with Greenstone.
Operating cash use -$5.9M, up 10% YoY from -$5.3M, reflecting higher expenses. Investing outflow -$50K (note receivable). Financing provided $7.2M net from warrant exercises ($7.7M gross less costs), minority contribution $10K, offset by $10K treasury buyback. Net cash increase $1.3M to $5.9M ending (balance sheet cash $7.2M includes treasuries). Total assets $7.8M (current $7.4M), liabilities $285K (low debt), equity $7.5M. Working capital $7.1M supports runway.
Management believes cash sufficient through March 2027 for operations, trials (CREATE-1 dosing, ADAPT follow-up), iPSC/AI programs. Plans additional capital via equity/debt for clinical advancement, commercialization. Risks: ongoing losses, dilution from offerings, regulatory hurdles (FDA clearances achieved for trials, Fast Track for CELZ-201-DDT), competition, need reimbursement for autologous products. Strategic priorities: advance CELZ-201 trials, BioDefense Initiative, partnerships.